Connect with us
AstraZeneca aims to nearly double its 2023 sales to $80 billion by 2030, focusing on cancer and rare disease treatments. CEO Pascal Soriot highlighted twelve potential...
Esteve reported a 10% growth in 2023, with net income of €710 million. Revenue grew 2% in Spain, 18% in the EU, and 9% globally, especially...
Until now, in the field of anti-obesity treatments, there was a drug that attracted attention: Ozempic. It is also made by Novo Nordisk and is very...
Goldman Sachs increased its stake in Grifols from 5.8% to 6.4%, amid a bearish attack by Gotham City Research, coinciding with Grifols' Q1 results. Melqart reduced...
In 2023, Spanish biotech companies secured 228 million euros in private financing, a 37% increase from 2022. This was announced at the AseBio Investor Day, organized...
BioNTech saw a sharp drop in profits, starting 2024 with a €315 million loss, down from a €502 million profit the previous year, and sales plummeting...
Sanofi acquires 4.9% of Novavax shares for $70 million, doubling the latter's valuation to around $1.4 billion. This investment is part of a co-exclusive licensing agreement...
Reig Jofre reported a 15% drop in profits in the first quarter of 2024, attributed to the absence of a biosimilar development milestone. However, overall growth...
Boehringer Ingelheim Spain significantly increased its R&D&I investment to 62.7 million euros, up 36% from the previous year, representing 11.5% of net sales. Their human health...
Zolgensma, Novartis' gene therapy for SMA, remains the world's most expensive medicine, priced between $1.2 million and $2.1 million per dose. Despite its high cost, it's...